Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
Company Details
- Employees
- 8
- Founded
- 2008
- Address
- Tempe, Arizona
- Phone
- (602)286-5284
- in****@****thx.com
- Industry
- Biotechnology
- Website
- capstonethx.com
- Keywords
- Co.
- HQ
- Tempe, Arizona
Capstone Therapeutics Questions
Capstone Therapeutics's helpline number is (602)286-5284
Capstone Therapeutics's website is capstonethx.com
Capstone Therapeutics's LinkedIn profile is https://www.linkedin.com/company/capstone-therapeutics
Capstone Therapeutics has
8 employees.
View email and phone details for 8
employees at Capstone Therapeutics.
Capstone Therapeutics's industry is
Biotechnology
Capstone Therapeutics's top competitors are
Dust Buddy,
Brookstone Partners,
Catamaran Bio,
Co-Diagnostics, Inc,
Capstone Development Services Co, Llc,
With Intelligence - Women's Summits,
Mti Instruments,
Instone,
Long Grove Pharmaceuticals,
Finchley Healthcare Ventures.
Capstone Therapeutics's support email address is investorinquiries@capstonethx.com
Capstone Therapeutics's categories are Biotechnology
Capstone Therapeutics's founding year is 2008
